Replies to post #4653 on ImClone Systems Inc (formerly IMCL)

[biophud]

Dew--I'm not sure, but my understanding is that companies like IMCL licence phage display technology from DYAX and use the technology themselves to isolate antibodies directed toward specific targets.

Here is a patent for anti-FGFR antibodies generated by IMCL using DYAX phage technology. Note that IMCL is the only assignee listed on the the patent.

http://appft1.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=45&f=G&l=50&co1=AND&d=PG01&s1=dyax&OS=dyax&RS=dyax

My understanding is that DYAX will collect milestones payments and royalities on future sales if a product comes to market.

Regards,

biophud